Candel Therapeutics (CADL) EBIT (2020 - 2025)
Candel Therapeutics recorded quarterly EBIT of -$15.8 million in Q4 2025, down 19.27% quarter-over-quarter from -$13.2 million in Q3 2025, and down 93.49% year-over-year from -$242.0 million in Q4 2024.
Candel Therapeutics' EBIT history runs 6 years deep, the most recent figure standing at -$15.8 million for Q4 2025.
- In Q4 2025, EBIT fell 93.49% year-over-year to -$15.8 million; the TTM figure through Dec 2025 stood at -$48.3 million (down 44.63% YoY), while the FY2025 annual figure was -$48.3 million, down 44.63% from the prior year.
- EBIT came in at -$15.8 million for Q4 2025 at Candel Therapeutics, down from -$13.2 million in the prior quarter.
- In the past five years, EBIT ranged from a high of -$4.7 million in Q1 2021 to a low of -$15.8 million in Q4 2025.
- A 5-year average of -$9.0 million and a median of -$8.8 million in 2022 frame the typical range for EBIT.
- Across the five-year window, EBIT tumbled 192.07% in 2021 and climbed 21.1% in 2024, its largest moves.
- Candel Therapeutics' EBIT stood at -$7.7 million in 2021, then declined by 4.66% to -$8.1 million in 2022, then decreased by 27.37% to -$10.3 million in 2023, then increased by 21.1% to -$8.1 million in 2024, then slumped by 93.49% to -$15.8 million in 2025.
- According to Business Quant data, EBIT over the past three periods registered -$15.8 million, -$13.2 million, and -$11.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.97 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -15.76 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 642.90 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 268.64 Mn |
| 10 | Candel Therapeutics | 449.62 Mn | 449.62 Mn | - | -15.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -15.75 Mn |
| Sep 30, 2025 | -13.21 Mn |
| Jun 30, 2025 | -11.18 Mn |
| Mar 31, 2025 | -8.13 Mn |
| Dec 31, 2024 | -8.14 Mn |
| Sep 30, 2024 | -8.76 Mn |
| Jun 30, 2024 | -8.57 Mn |
| Mar 31, 2024 | -7.90 Mn |
| Dec 31, 2023 | -10.32 Mn |
| Sep 30, 2023 | -8.86 Mn |
| Jun 30, 2023 | -9.58 Mn |
| Mar 31, 2023 | -9.63 Mn |
| Dec 31, 2022 | -8.10 Mn |
| Sep 30, 2022 | -8.88 Mn |
| Jun 30, 2022 | -8.75 Mn |
| Mar 31, 2022 | -8.99 Mn |
| Dec 31, 2021 | -7.74 Mn |
| Sep 30, 2021 | -8.03 Mn |
| Jun 30, 2021 | -5.30 Mn |
| Mar 31, 2021 | -4.66 Mn |
| Dec 31, 2020 | -6.13 Mn |
| Sep 30, 2020 | -2.75 Mn |
| Jun 30, 2020 | -2.62 Mn |